Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study

Vagliano, Liliana; Feraut, C; Gobetto, G; Trunfio, A; Errico, Alessandro; Campani, V; Costazza, G; Mega, Andrea; Matozzo, Vincenzo; Berni, Mateus; Alberani, F; Banfi, Marina Marialuisa; Martinelli, Luigi; Munaron, Susanna; Orlando, Laura; Lubiato, L; Leanza, Silvana; Guerrato, R; Rossetti, Antonio Maria; Messina, Maria Francesca; Barzetti, L; Satta, Giovanni; Dimonte, Valerio

doi:10.1038/bmt.2010.184

Cited by 94 publications

(93 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,6 Genel olarak, çocukluk çağı kanserlerinde OM'nin sıklığı tedavinin tipine bağlı olarak %52-81 oranında değişmektedir. [3][4][5][7][8][9] Akut lenfoblastik lö-semi için KT tedavisi gören çocuk hastalarda OM %46 oranında görülür iken, yoğun miyeloablatif KT alanlarda ise %90-100 oranında görülmektedir. Kök hücre nakil sonrasında ise bu oran %100'lere ulaşmaktadır.…”

Section: Derlemeunclassified

Oral Mucositis Results in Pediatrics Cancer Patients: Review

Bulut¹

2016

Turkiye Klinikleri J Nurs Sci

View full text Add to dashboard Cite

Section: Derlemeunclassified

Oral Mucositis Results in Pediatrics Cancer Patients: Review

Bulut¹

2016

Turkiye Klinikleri J Nurs Sci

View full text Add to dashboard Cite

“…Mas, o TCTH é considerado um procedimento de risco para o paciente devido às diversas complicações que podem surgir (CRADDOCK, 2008). A mucosite bucal é uma complicação que frequentemente se manifestada nesta clientela e é considerado um problema grave em decorrência das altas doses de quimioterapia e/ou radioterapia empregados no regime de condicionamento do TCTH (BONASSA, 2005;VAGLIANO et al, 2011). Assim, dentre os pacientes que estão em alto risco para desenvolver mucosite estão os submetidos ao TCTH alogênico (SONIS, 2009).…”

Section: Discussionunclassified

“…Estudos têm evidenciado que a incidência de mucosite bucal em pacientes transplantados de células-tronco hematopoéticas varia entre 70% a 99% (WARDLEY et al, 2000;SONIS et al, 2001;STIFF, 2001;SHEA et al, 2003;VERA-LLONCH et al, 2007; SILVA; BUSSOLOTI-FILHO, 2007;OHBAYASHI et al, 2008;VAGLIANO et al, 2011).…”

Section: Mucosite Bucalunclassified

“…A severidade dessas manifestações pode variar, contudo, sabe-se que pacientes adultos submetidos ao TCTH alogênico possuem 2,88 mais chance de desenvolver mucosite severa do que os submetidos ao TCTH autólogo (VAGLIANO et al, 2011).…”

Section: Mucosite Bucalunclassified

“…Pode permanecer por até três semanas após o procedimento, porém, na maioria dos casos a duração é de 10 a 14 dias. A sua resolução, frequentemente, ocorre com a reconstituição da medula óssea (BLIJLEVENS; DONNELLY; DEPAUW, 2005;BUSSOLOTI-FILHO, 2007;OHBAYASHI et al, 2008;VAGLIANO, et al, 2011).…”

Section: Mucosite Bucalunclassified

See 2 more Smart Citations

Enxaguatório bucal de chamomilla recutita (camomila): preparo e aplicação na mucosite bucal

Braga¹,

Carvalho²

View full text Add to dashboard Cite

A Alessandra e Kátia A Alessandra e Kátia A Alessandra e Kátia A Alessandra e Kátia obrigada pela valiosa ajuda no desenvolvimento deste trabalho.As amigas e colegas de trabalho da EERP As amigas e colegas de trabalho da EERP As amigas e colegas de trabalho da EERP As amigas e colegas de trabalho da EERP----USP, Andréa, Ana A náusea foi a única manifestação relatada por dois pacientes durante a realização do bochecho. Dessa forma, os resultados evidenciaram uma possível ação do enxaguatório contendo Chamomilla recutita na redução da incidência da mucosite, na dose de 1%, em pacientes submetidos ao TCTH, bem como uma menor intensidade de mucosite graus II e III nos grupos que receberam as doses de 1 e 2%. Contudo, para confirmar estes achados faz-se necessário ampliar a amostra deste estudo empregando o método aqui desenvolvido. O enxaguatório bucal de Chamomilla recutita nas dosagens de 0,5; 1 e 2% foi bem tolerado pelos pacientes e demonstrou ser seguro, uma vez que nenhum efeito adverso moderado ou severo foi identificado. Oral mucositis (OM) is an inflammatory complication frequently manifested by patients undergoing Hematopoietic Stem Cell Transplantation (HSCT), as a result of aggressive treatment regimen employed. However, prevention and treatment are still controversial in literature. Chamomile has been used for therapeutic purposes for centuries and has been employed in some HSCT services for both prevention and treatment of OM. However, no studies that investigate its action in this clientele have been identified. Thus, this study aimed to compare the incidence, intensity and duration of oral mucositis in adult patients undergoing HSCT according to the doses (0.5; 1 or 2%) of Chamomilla recutita in mouthwash. The study was carried out in four stages. First an integrative literature review was conducted, in order to identify the scientific evidence available regarding the use of Chamomilla recutita to reduce the occurrence and intensity of inflammatory processes. It was evidenced that Chamomilla recutita is likely to have topic anti-inflammatory action, for several inflammatory disorders. Considering the results of this review and those obtained with studies in vitro and in animals, it was deemed appropriate to develop the clinical study. At the second stage, the plant drug was selected, physical-chemical and microbiological analysis were carried out and quantification of apigenin-7-glucoside was determined. Tests identified the excellent quality of capitula from the selected sample. In sequence, at the third phase, the fluid extract was obtained, whose analysis showed the maintenance of quality and content of active principle. Subsequently, the extract was successfully incorporated in three formulations of mouthwash, according to the dosages proposed for the clinical study (0.5; 1 and 2%). At last, a clinical study with 23 patients who underwent allogeneic HSCT was performed, randomized into four groups. Regarding the incidence of mucositis, 5 (83.3%) patients in group B who received the mouthwash with ...

show abstract

Management of early and late toxicities of autologous hematopoietic stem cell transplantation

Pingali¹,

Nieto²

2015

Clinical Guide to Transplantation in Lymphoma

View full text Add to dashboard Cite

Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study

Cited by 94 publications

References 12 publications

Oral Mucositis Results in Pediatrics Cancer Patients: Review

Oral Mucositis Results in Pediatrics Cancer Patients: Review

Enxaguatório bucal de chamomilla recutita (camomila): preparo e aplicação na mucosite bucal

Management of early and late toxicities of autologous hematopoietic stem cell transplantation

Contact Info

Product

Resources

About